Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20090626 | 0.79 | HDAC1 (0.47) | HDAC1HDAC6KDM4EPOLBKCNQ3 | |
| SCHEMBL14061762 | 0.78 | HDAC1 (0.36) | HDAC1HDAC6DGAT1 | |
| SCHEMBL1725915 | 0.78 | HDAC1 (0.36) | HDAC1HDAC6DGAT1 | |
| SCHEMBL1725523 | 0.77 | HCAR3 (0.58) | HDAC1HDAC6MAPT | |
| SCHEMBL5782529 | 0.77 | KDM4E (0.45) | HDAC1HDAC6KDM4EKCNQ3KCNQ2 | |
| SCHEMBL5783122 | 0.77 | RAB9A (0.48) | HDAC1HDAC6KDM4EKCNQ3KCNQ2 | |
| SCHEMBL312493 | 0.76 | HDAC1 (0.61) | HDAC1HDAC6KDM4EGAASMN1; SMN2 | |
| SCHEMBL21004360 | 0.76 | HDAC1 (0.61) | HDAC1HDAC6KDM4EPOLBCTDSP1 | |
| SCHEMBL12204514 | 0.76 | HDAC1 (0.52) | HDAC1HDAC6KDM4EPOLBKCNQ3 | |
| SCHEMBL610296 | 0.76 | NAPRT (0.52) | POLBKCNQ3KCNQ2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113603684-B | 1,2, 4-oxadiazole Nrf2 activator-tac Lin Pinge product and preparation method and application thereof | 中国药科大学 | 2023-12-19 | — | — | CN | disclosed |
| CN-110669044-B | Donepezil-oxadiazole fusion compound and preparation method and application thereof | 中国药科大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-108289448-B | Microbicidal oxadiazole derivatives | 先正达参股股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-108430997-B | Microbicidal oxadiazole derivatives | 先正达参股股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-110669044-A | Donepezil-oxadiazole fusion compound and preparation method and application thereof | 中国药科大学 | 2020-01-10 | — | — | CN | disclosed |
| WO-2018072697-A1 | OXADIAZOLE RING-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, COMPOSITE, AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2018-04-26 | — | — | WO | disclosed |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2974727-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9186407-B2 | Pharmaceutical compositions and their methods of use | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2226074-B1 | Pharmaceutical compositions and their methods of use | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2226074-A2 | Pharmaceutical compositions and their methods of use | Abbott Laboratories (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2101763-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073942-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | HDAC1 736/4885HDAC6 927/4885KDM4E 3738/4885 |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | OXA1L, CYP11B2, CYP1B1 | HDAC1 892/4885HDAC6 308/4885KDM4E 2438/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | HDAC1 1924/4885HDAC6 1195/4885KDM4E 1022/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | HDAC1 1924/4885HDAC6 1195/4885KDM4E 1022/4885 |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | HDAC1 593/4885HDAC6 1558/4885KDM4E 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.